Canvuparatide

DB18658InvestigationalProtein Based Therapies

Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.

Mechanism: Pharmacologically active on Parathyroid hormone/parathyroid hormone-related peptide receptor
Curator reviewed
Code names: MBX-2109

Resolves to

Compound

Targets

What you can answer from here — as of July 20, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Canvuparatide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.